Gordon Fox • April 14, 2025
Decisions in HCM

by Victoria-Theresa Wyatt and            Gordon Fox:  First in a series

What is Shared Decision-Making?

Shared decision-making is a term used a lot in healthcare settings and medical education these days. It represents the latest understanding of the physician's and patient’s roles and responsibilities in helping patients make decisions about their health. Shared decision-making is intended to combine patient preferences, the physician's clinical expertise and the latest medical research to make more informed healthcare decisions. 


What typically goes into making a decision? 

  • Identification - Identifying the decision you would like to make (For example: Should I get pregnant as an HCM patient?). How does this decision affect the many other potential issues I might have as an HCM patient (Would my HCM make my pregnancy risky? What is the chance my child will inherit my HCM?)?
  • Analysis  - Bring together the information you have available (such as risk factors and assessment, quality of life concerns, health history, doctor's recommendations, etc.).  How do I get more and more accurate information to help make this decision?
  • Evaluation  - Using the information above to make your decision (in conjunction with your medical team and loved ones, like in treatment plans). 



What does this look like in real life? Imagine you are planning a vacation. HCM might cause you to make additional decisions or consider additional factors when choosing where to go or what to do. If your HCM is  stable and you are not very symptomatic, the proximity of quality cardiac care may not be at the front of your mind when choosing your vacation destination. If you are an HCM patient in advanced heart failure, you may want to vacation in areas where you can be certain you can obtain care. You might need to consider whether your trip requires strenuous activity or you can opt out of those activities. Perhaps your doctor has told you to avoid certain activities that might put you or others at risk if you have an issue and you want to take that into consideration when planning your itinerary.


What this series will do.


In this series of blog posts, we hope to break down the decision-making process with HCM, understanding risk, how to interpret it as the doctors may explain it, and how it applies to you, as well as discuss some common areas where HCM may affect your decision-making process. Using the information provided in this series, you will feel better equipped to apply some of the information you receive to make the right decisions for you! 


HCMA Blog

By Erica Friedman June 26, 2025
Investigative journalists Debbie Cenziper, Megan Rose, Brandon Roberts and Irena Hwang from Pro Publica and NPR have concluded a 14-month long investigation into the quality of generic drugs coming into the United States from overseas. Among the many voices that spoke up for American patients was HCMA Founder and CEO, Lisa Salberg who has felt the effects of low-quality drugs personally. Salberg believes that fixing this problem is something we can do, even in this time, when even health care is highly politicized. Read the key takeaways from ProPublica’s 14-month investigation into the FDA’s oversight of foreign drugmakers in Threat in Your Medicine Cabinet: The FDA’s Gamble on America’s Drugs .
A light blue and dark blue paintbrush stroke intersect to make a stylized
By Erica Friedman June 18, 2025
Alnylam press release on the European Commission approval of AMVUTTRA® (vutrisiran) forwild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication
Light & dark blue brush stroke that intersect create an abstract letter 'a' next to the word Alnylam
By Erica Friedman June 17, 2025
AMVUTTRA® (vutrisiran) has been approved by the U.S. Food and Drug Administration (FDA) to treat ATTR-CM in adults.
More Posts